Scientific Committee
Greg Hinkle Alnylam Pharmaceuticals
Frank Bennett Ionis Pharmaceuticals
Ryan Flynn Boston Children's Hospital
Barbara Cheifet Nature Biotechnology
Peter Kirkpatrick Nature Reviews Drug Discovery
Florian Ullrich Nature
Alnylam Pharmaceuticals
Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize-winning discovery into an entirely new class of medicines, which we believe has the potential to help people all over the world to live longer, healthier, and fuller lives. Through pioneering science, unwavering commitment to patients, and our approved therapies and deep pipeline of investigational RNAi therapeutics, we have cemented our reputation for innovation and leadership in RNAi.
Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize-winning discovery into an entirely new class of medicines, which we believe has the potential to help people all over the world to live longer, healthier, and fuller lives. Through pioneering science, unwavering commitment to patients, and our approved therapies and deep pipeline of investigational RNAi therapeutics, we have cemented our reputation for innovation and leadership in RNAi.
Ionis Pharmaceuticals
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has five marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.
Boston Children's Hospital
Boston Children’s Hospital is dedicated to improving and advancing the health and well-being of children around the world through its life-changing work in clinical care, biomedical research, medical education and community engagement.
Boston Children's is ranked the #1 pediatric hospital in the world by Newsweek and among best in the nation by U.S. News and World Report. It is home to the world's largest pediatric research enterprise, and it is the leading recipient of pediatric research funding from the National Institutes of Health. It is the primary pediatric teaching hospital for Harvard Medical School. Boston Children’s treats more children with rare diseases and complex conditions than any other hospital.
Harvard Stem Cell Institute
The Harvard Stem Cell Institute (HSCI) is dedicated to pursuing the promise of stem cell science and regenerative medicine. We are a network of more than 325 research faculty and their labs across the university’s schools, centers, teaching hospitals, and partner companies, working together to advance stem cell biology and discover new treatments for patients.
The Harvard Stem Cell Institute (HSCI) is dedicated to pursuing the promise of stem cell science and regenerative medicine. We are a network of more than 325 research faculty and their labs across the university’s schools, centers, teaching hospitals, and partner companies, working together to advance stem cell biology and discover new treatments for patients.
Nature
Nature is a weekly international journal publishing the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.
Nature is a weekly international journal publishing the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.
Nature Biotechnology
Nature Biotechnology is a monthly journal covering the science and business of biotechnology. It publishes new concepts in technology/methodology of relevance to the biological, biomedical, agricultural and environmental sciences as well as covers the commercial, political, ethical, legal, and societal aspects of this research. The first function is fulfilled by the peer-reviewed research section, the second by the expository efforts in the front of the journal. We provide researchers with news about business; we provide the business community with news about research developments.
Nature Biotechnology is a monthly journal covering the science and business of biotechnology. It publishes new concepts in technology/methodology of relevance to the biological, biomedical, agricultural and environmental sciences as well as covers the commercial, political, ethical, legal, and societal aspects of this research. The first function is fulfilled by the peer-reviewed research section, the second by the expository efforts in the front of the journal. We provide researchers with news about business; we provide the business community with news about research developments.
Nature Reviews Drug Discovery
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering the entire field, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in fast-moving areas such as new drug approvals, patent law and emerging industry trends.
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering the entire field, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in fast-moving areas such as new drug approvals, patent law and emerging industry trends.